Definitive Healthcare (NASDAQ:DH) Updates Q2 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.08-$0.09 for the period, compared to the consensus earnings per share estimate of $0.09. The company issued revenue guidance of $62.0-$63.5 million, compared to the consensus revenue estimate of $65.19 million. Definitive Healthcare also updated its FY24 guidance to $0.36-$0.38 EPS.

Definitive Healthcare Trading Up 0.6 %

Shares of Definitive Healthcare stock traded up $0.03 on Friday, hitting $5.20. 2,047,511 shares of the company’s stock traded hands, compared to its average volume of 658,212. Definitive Healthcare has a one year low of $4.38 and a one year high of $12.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31. The stock has a market capitalization of $612.51 million, a PE ratio of -2.90, a price-to-earnings-growth ratio of 6.12 and a beta of 1.41. The firm’s 50-day moving average price is $7.61 and its two-hundred day moving average price is $8.27.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. The firm had revenue of $65.93 million for the quarter, compared to the consensus estimate of $66.01 million. On average, research analysts expect that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DH. Stifel Nicolaus reduced their price target on Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a research report on Wednesday. Canaccord Genuity Group decreased their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a research report on Wednesday. Needham & Company LLC restated a hold rating on shares of Definitive Healthcare in a research note on Wednesday. Barclays decreased their price objective on Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a report on Thursday. Finally, Morgan Stanley lowered Definitive Healthcare from an overweight rating to an equal weight rating and dropped their target price for the stock from $11.50 to $9.00 in a report on Wednesday. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $9.94.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.